Key facts
- Xcell Biosciences’s last known valuation is $65.5M (Sep 2021).
- It has raised $60.4M across 3 recorded rounds; the latest was Later Stage VC ($27.5M) in Dec 2024.
- Notable investors include Lightspeed Venture Partners, Viking Global Investors, DST Global, Berkeley SkyDeck, Alexandria Venture Investments — 21 tracked in total.
- Xcell Biosciences has filed 3 Form Ds with the SEC since 2017, most recently Dec 2024 ($1.4M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Xcell Biosciences
Funding rounds
3 roundsAbout Xcell Biosciences
Developer of a bench-top primary cell control system designed to advance immunotherapy research and manufacturing, empowering scientists with better tools for cell maintenance, expansion, and control. The company's technology supports a range of primary cell types, including immune, stem, and tumor cells, enabling clients with predictive therapy development and improved clinical outcomes.
- Industry
- Discovery Tools (Healthcare)
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2012
- Employees
- 29
- Website
- xcellbio.com/
- Ownership
- Privately Held (backing)
Xcell Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xcell Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xcell Biosciences in its N-PORT filings yet. We sweep new filings monthly.